Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26620515 | 1.00 | PIK3CD (0.52) | PIK3CDPIK3CAGPR119PIK3CBPIK3CG | |
| SCHEMBL16771257 | 0.94 | GPR119 (0.52) | GPR119MAPTCYP2C9CYP2C19GAA | |
| SCHEMBL20135004 | 0.88 | PIK3CD (0.56) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL20135006 | 0.88 | PIK3CD (0.56) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL26774156 | 0.86 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL31695270 | 0.84 | PIK3CD (0.55) | PIK3CDPIK3CAPIK3CBMEN1KMT2A | |
| SCHEMBL2524957 | 0.82 | PIK3CD (0.50) | PIK3CDPIK3CAGPR119PIK3CBPIK3CG | |
| SCHEMBL29629007 | 0.82 | PIK3CD (0.50) | PIK3CDPIK3CAGPR119PIK3CBPIK3CG | |
| SCHEMBL1957219 | 0.82 | PIK3CD (0.50) | PIK3CDPIK3CAGPR119PIK3CBPIK3CG | |
| SCHEMBL16771100 | 0.82 | GPR119 (0.51) | GPR119MAPTCYP2C9CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4096661-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | Kamari Pharma Ltd. (IL) | 2022-12-07 | — | — | EP | disclosed |
| US-20220332697-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | KAMARI PHARMA LTD. (IL) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332697-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | RDX, HAX1, F12 | PIK3CD 4429/4885PIK3CA 2358/4885GPR119 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.